Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...
In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...
Moreover, the outlook for Syfovre is not promising ... Additionally, the anticipated market share gains by Izervay pose a significant challenge, and price discounts are not fully factored in as growth ...
Analyst Joseph Stringer of Needham maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report), reducing the price target ...
Medpage Today on MSN4d
FDA Grants Market Authorization to Light-Therapy System for Dry AMDLumiThera's Valeda Light Delivery System generates light at different wavelengths to stimulate and improve the function of retinal mitochondria. The photobiomodulation (PBM) system is the first ...
Investor's Business Daily on MSN5d
Apellis Dives As Worse-Than-Expected Syfovre Sales Add Fuel To Market WoesApellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...
Izervay and Syfovre are addressing a potentially enormous market, leading analysts to previously predict blockbuster sales levels for both drugs, although, Apellis' drug has been linked to side ...
While Syfovre targets complement C3, Izervay – formerly known as Zimura – is a C5 inhibitor. In a bid to differentiate the new product from its rival, Astellas said that Izervay is the only GA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback